SCHEMBL20340876

SCHEMBL20340876

CC(N)CC(=O)c1ccccc1NC=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.39
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.35
NPC1 O15118 2/20 0.35
NFKB1 P19838 2/20 0.35
RAB9A P51151 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 2/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 1/20 0.35
CASP1 P29466 1/20 0.35
GAA P10253 1/20 0.35
DHODH Q02127 1/20 0.35
OR51E2 Q9H255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20340875 0.85 RXFP1 (0.37) RXFP1KDM4EALDH1A1NPC1NFKB1
SCHEMBL17623477 0.85 RXFP1 (0.39) RXFP1KDM4EALDH1A1NPC1NFKB1
SCHEMBL29934103 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL16801822 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL148492 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL31520048 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL31520056 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL145723 0.84 KDM4E (0.51) RXFP1KDM4EPKMHIF1ATDP1
SCHEMBL12911463 0.79 RXFP1 (0.43) RXFP1KDM4EALDH1A1NPC1RAB9A
SCHEMBL15628045 0.78 RXFP1 (0.36) RXFP1HSP90AA1HSP90AB1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3685849-A1 TERIPARATIDE-CONTAINING LIQUID PHARMACEUTICAL COMPOSITION HAVING EXCELLENT STABILITY Asahi Kasei Pharma Corporation (JP) 2020-07-29 EP disclosed
US-10683335-B2 Freeze-dried preparation containing high-purity PTH and method for producing same ASAHI KASEI PHARMA CORPORATION (JP) 2020-06-16 US disclosed
US-10011643-B2 Freeze-dried preparation containing high-purity PTH and method for producing same ASAHI KASEI PHARMA CORPORATION (JP) 2018-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011643-B2 Freeze-dried preparation containing high-purity PTH and method for producing same PTH1R, PTMS, VIP RXFP1 260/4885HSP90AA1 1909/4885HSP90AB1 2187/4885
US-10683335-B2 Freeze-dried preparation containing high-purity PTH and method for producing same PTH1R, PTMS, VIP RXFP1 436/4885HSP90AA1 900/4885HSP90AB1 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.